What is NeuraLight?
Founded in 2021, NeuraLight operates at the forefront of medical technology, specifically targeting the digitization of neurological assessments. The company addresses a significant gap in the healthcare market by providing objective, data-driven insights for patients suffering from complex neurological disorders. By moving away from subjective clinical observations toward quantifiable digital biomarkers, NeuraLight aims to improve patient outcomes and streamline the diagnostic process for clinicians globally. Its market position is bolstered by a robust intellectual property strategy and a focus on scalable, enterprise-level health solutions.
How much funding has NeuraLight raised?
NeuraLight has raised a total of $30.5M across 2 funding rounds:
Angel/Seed
$5.5M
Series A
$25M
Angel/Seed (2021): $5.5M with participation from VSC Ventures, Kli, Tuesday, MSAD, and Operator Partners
Series A (2022): $25M led by Samsung NEXT, Koch Disruptive Technologies, David Golan, Lily Sarafan, Breyer Capital, Chris Mansi, and VSC Ventures
Key Investors in NeuraLight
Samsung NEXT
Samsung NEXT is a venture arm that provides software and services to complement global hardware footprints, focusing on product development, investment, and strategic partnerships.
Breyer Capital
Breyer Capital is an independent global venture capital firm that focuses on long-term, idea-driven investments, particularly in artificial intelligence and machine learning.
VSC Ventures
VSC Ventures is a strategic investment firm that supports early-stage technology companies by providing capital and operational expertise to drive market disruption.
What's next for NeuraLight?
With the recent capital injection, NeuraLight is expected to accelerate its product development roadmap and expand its clinical validation studies. The company is likely to focus on scaling its platform to meet the demands of large-scale healthcare providers and research institutions. As it transitions into a more mature phase of its lifecycle, the firm will likely prioritize strategic partnerships that facilitate the integration of its diagnostic tools into existing electronic health record systems. The focus remains on achieving regulatory milestones and demonstrating the long-term clinical efficacy of its proprietary neurological analysis engine, ensuring that the company remains a leader in the rapidly evolving digital neurology landscape.
See full NeuraLight company page
